TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01901705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indigo naturalis ointment
Description: The Indigo naturalis ointment was composed of a 1:10 mixture of Indigo naturalis powder and a vehicle consisting of Vaseline: microcrystalline wax: olive oil (5:6:9 ratio)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was a mixture of blue dye powder (54.8% Indigo carmine aluminum lake \[Blue #32\] and 45.2% Allura Red AC aluminum lake \[Red #40\] powders), Vaseline, microcrystalline wax, and olive oil.
Study: NCT01375660

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50K vitamin D2
Description: Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
Study: NCT02694757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ostom-i device
Description: The Ostom-i alert (OIA) is a discrete novel device which clips onto any ostomy bag from edge to edge and measures the horizontal tension between the edges over time, as a result of stool volume in the ostomy. It is an FDA approved medical device.
Study: NCT02412514

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV (three dose)
Description: bOPV administered at 6, 10, and 14 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV (two dose)
Description: bOPV administered at 10 and 14 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Description: IPV administered at 6 weeks of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Description: IPV administered at 6 weeks of age
Study: NCT00812760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa
Description: 1 tablet of 200 mg levodopa plus 50 mg benserazide
Study: NCT02650921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lyft with Lidocaine
Description: An injectable gel of Hyaluronic Acid and Lidocaine
Study: NCT04097782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antenat education
Description: Antenatal education group The primiparous pregnant women assigned to the intervention group participated in education classes in groups of 8-10 people. Pregnant women were given structured antenatal education twice a week for two weeks (240 minutes). The total education time was 16 hours. Each session comprised 150 minutes presentation of theoretical knowledge, 45 minutes warm-up and stretching exercises, and 45 minutes relaxation exercises.
Study: NCT02530905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP-4045
Description: SRP-4045 solution for IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP-4045
Description: SRP-4045 solution for IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SRP-4045 placebo-matching solution for IV infusion.
Study: NCT00183521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Raise-CO2 breathing regulation training
Description: Reverse hyperventilation (defined by low arterial CO2) is often characteristic of individuals with panic disorder. Participants will be randomly assigned to one of three groups: raise-CO2 breathing, lower-CO2 breathing, or a control group. Participants in the raise-CO2 group will be taught techniques to recover from hyperventilation faster.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower-CO2 breathing regulation training
Description: According to the false suffocation alarm theory, anxiety is experienced when an overly sensitive hypothalamic mechanism is triggered by rising pCO2. Participants in the lower-CO2 group will be taught techniques to reach hyperventilation levels, then switch to breathing techniques that reduce hyperventilation symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in the control group will not be taught any breathing techniques but will be included in all assessments.
Study: NCT00840125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150mg tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 30 mg/m2 days 1,8 of 22 days cycles, up to 6 cycles
Study: NCT02986776

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Care
Description: 21 days of inpatient substance misuse treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Care
Description: 21 days of inpatient substance misuse treatment
Study: NCT03828981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fast-track recovery program
Description: Pre-operative: fast-track management counseling, fast-track educational video,tobacco cessation, daily physical activity, light meal 6 hours and clear liquids up to 2 hours before surgery, no bowel preparation, a warm blanket, medication.~Intra-operative: vaginal wound infiltrative anesthesia, early remove of urine catheter.~Post-operative: early oral intake liquids and food, early mobilization, avoiding opioids by use of pregabaline for postoperative pain.
Study: NCT03013634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Equal volume normal saline substitute for dexmedetomidine
Study: NCT00892892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilmenidine
Description: 1 mg Rilmenidine per day versus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrendipine
Description: 20 mg Nitrendipine per day
Study: NCT04403997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chromoendoscopy
Description: Chromoendoscopy is an endoscopic technique used in the follow-up of inflammatory bowel disease of long evolution. Chromoendoscopy, through the application of specific dyes used directly on the intestinal mucosa, promotes the visualization of mucosal lesions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Description: Chromoendoscopy is an endoscopic technique used in the follow-up of inflammatory bowel disease of long evolution. Chromoendoscopy, through the application of specific dyes used directly on the intestinal mucosa, promotes the visualization of mucosal lesions.
Study: NCT02246322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25G needle
Description: All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 22G needle
Description: All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
Study: NCT02137135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HAD scale
Description: The anxiety/depression scale (HAD) was used to assess anxiety and depression.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HAD scale
Description: The anxiety/depression scale (HAD) was used to assess anxiety and depression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The SF 12 test
Description: The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The SF 12 test
Description: The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual analogue score
Description: Visual analogue score vas used to evaluate pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual analogue score
Description: Visual analogue score vas used to evaluate pain.
Study: NCT04109521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training, certification and marketing
Description: The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
Study: NCT01464112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-2641585 / VELCADE / Dexamethasone
Description: JNJ-26481585: type=range, unit=mg, number=6 to 12, form=capsules, route=oral use, on Days 1, 3, and 5 of each week. VELCADE: type=exact, unit=mg/m2, number=1.3, form=powder for solution for injection, route=subcutaneous use, on Days 1, 4, 8, and 11 of each 21-day cycle (Cycles 1 to 8) and on Days 1, 8, 15, and 22 of each 35-day cycle (Cycles 9-11). Dexamethasone: type=exact, unit=mg, number=20, form=tablets, route=oral use, on the day of and after VELCADE.
Study: NCT02559063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vision-based speed of processing training
Description: computerized cognitive tasks addressing vision-based speed of processing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental leisure activities
Description: computerized cognitive tasks addressing different aspects of executive function
Study: NCT01163825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve Growth Factor
Description: Encapsulated cell biodelivery of Nerve Growth Factor (NGF) to the basal forebrain nuclei of the brain by multiple implantable devices housing NGF-secreting human cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve Growth Factor
Description: Encapsulated cell biodelivery of Nerve Growth Factor (NGF) to the basal forebrain nuclei of the brain by multiple implantable devices housing NGF-secreting human cells
Study: NCT03610113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplasty
Description: The implantation of reverse shoulder prosthesis, and reattachment of greater and lesser tuberosities
Study: NCT04198844

Intervention type: DRUG
Intervention: warfarin
Description: warfarin user

Intervention type: DRUG
Intervention: apixaban
Description: apixaban user
Study: NCT03921463

Intervention type: OTHER
Description: This is an observational study

Intervention type: OTHER
Description: This is an observational study
Study: NCT02495415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide
Description: Fenretinide intravenous emulsion administered as a continuous intravenous infusion for 5 days, once every 3 weeks in relapsed/refractory PTCL patients.
Study: NCT01774435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3342
Study: NCT00693628

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: compression shrinker
Description: Two levels of compression: 20-30 mmHg or 30-40 mmHg shrinker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: compression shrinker
Description: Two levels of compression: 20-30 mmHg or 30-40 mmHg shrinker
Study: NCT04060147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally once daily
Study: NCT04421508

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: INOpulse
Description: Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.
Study: NCT01639092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir 300mg Daily Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir 300mg Daily Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Entecavir 1 mg daily Oral
Study: NCT02482090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 is administered on day -5 to day -1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL infusion
Description: The maximum number of expanded TILs are infused over 30-45 minutes on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 is administered as a continous i.v. infusion in a decrescendo regimen (18 MIU/m3 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU/m2 IL-2 over 24 hours followed by 4,5 MIU/m2 IL-2 over another 24 hours for three days).
Study: NCT00834522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron hydrochloride 1 mg tablets
Description: 2 x 1 mg, single dose non-fasting
Study: NCT03053674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral and written explanation
Description: Oral and written explanation on importance of post-partum influenza vaccination for the health of their newborn infant
Study: NCT00834522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kytril® 1 mg tablets
Description: 2 x 1 mg, single dose non-fasting
Study: NCT02702102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PBR28
Description: Up to 20 millicuries
Study: NCT06151678

Intervention type: OTHER
Intervention: Pain Education
Description: Pain education was offered to health professionals and the general public using with a focus on pain neuroscience. This was offered with a lecture from pain scientists, personal reflections from individuals with lived experience and health care professionals.

Intervention type: OTHER
Intervention: Pain Education
Description: Pain education was offered to health professionals and the general public using with a focus on pain neuroscience. This was offered with a lecture from pain scientists, personal reflections from individuals with lived experience and health care professionals.

Intervention type: OTHER
Intervention: Pain Education
Description: Pain education was offered to health professionals and the general public using with a focus on pain neuroscience. This was offered with a lecture from pain scientists, personal reflections from individuals with lived experience and health care professionals.
Study: NCT00773422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: 25 mg/day, with 1-week lead-in medication period. The starting dose is 0 mg/day for days 1-3, followed by 12.5mg/day for day 4, followed by 25mg/day for days 5-7, plus during the laboratory session (day 8).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: 2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: 2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05203562

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suction evacuation
Description: both groups underwent complete mole evacuation using suction curettage.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suction evacuation
Description: both groups underwent complete mole evacuation using suction curettage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole tablets
Description: Group II Patients received 5mg(2tablets 2.5gm) daily letrozole for 10 days after complete mole evacuation
Study: NCT04531605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YBank program
Description: Adolescents participated in a 12-week peer-led life skills trainings at clinics and received financial incentives via mobile money upon clinic attendance and demonstration of suppressed viral load.
Study: NCT02519491

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Allen Test
Description: The Modified Allen's Test (MAT) will be performed in a well-lit room on both of the participant's hands. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iphone artery assessment
Description: The iRADIAL iPhone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's thumb and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
Study: NCT04064892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The intervention will use peer mentors, motivational interviewing, and technology (Fitbit, Fitbit Coach App, \& Fitbit message board) to support behavior change. All participants will receive phone or video calls from their peer mentors every other week, and interact with their peer mentor and other participants through a private Fitbit message board at least weekly. Peer mentors will use Fitbit data to identify participants who need additional support to increase their activity.
Study: NCT02120937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT-C Therapy
Description: Mindfulness Based Cognitive Therapy for Children is a manualized psychotherapeutic intervention that combines mindfulness techniques with certain features of cognitive behavioral therapy. This particular protocol for youth includes weekly group sessions, regular home practice, and the core curriculum of formal mindfulness practices (e.g., body scan, sitting, movement, and walking meditations).
Study: NCT03637556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DST-0509
Description: Novel iron chelator with improved absorption characteristics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jadenu
Description: Commercial iron chelator with standard absorption characteristics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exjade
Description: Commercial iron chelator with standard absorption characteristics
Study: NCT01615198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: 10 mg, 20 mg, 40 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 100 mg, 200 mg tablets
Study: NCT04023539

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamomum zeylanicum
Description: Capsules of 2 g cinnamomum zeylanicum orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT03235180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride
Description: Subjects will receive ultrasound (US) imaging of the terminal ileum without and with sulfur hexafluoride contrast at baseline, 4 week and 6 months. Subjects will receive one to two milliliters of the contrast agent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Elastography
Description: Subjects will receive US Imaging with the GE Logiq E9 Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Vascularity
Description: Subjects will receive US Imaging with the Verasonics Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Enterography (MRE)
Description: Subjects will receive MRE imaging at baseline and 6 months as part of regular clinical care.
Study: NCT00691119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation and Visualization Therapy
Description: Twenty minutes of facilitated relaxation and visualization therapy five days a week for six weeks. Self practice of 20 minutes per day for the next six weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Facilitated health education sessions, twenty minutes, five times a week for six weeks.
Study: NCT02249247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of BIIL 284 BS tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose of BIIL 284 BS tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of BIIL 284 BS tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03157570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 7-min High Intensity Interval Training with 12 different exercises (each exercise 30 seconds continuously with 10 seconds rest interval)
Study: NCT05520164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening the maternal heart sound during the invasive interventions
Description: Heart sounds of the newborns' own mothers were recorded on the voice recorder with the help of a hand doppler device. This sound was listened by the newborns in the experimental group during the heel blood procedure.